Watchful Waiting in Patients With Good and Intermediate Risk Metastatic Renal Cell Carcinoma; an Imaging Guided Observational Approach. Part of: Towards Patient Tailored Cancer Treatment Supported by Molecular Imaging. IMPACT Study: Imaging Patients for Cancer Drug Selection
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Sep 2019
Price : $35 *
At a glance
- Drugs Girentuximab Zr-89 (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms IMPACT-RCC
- 11 Apr 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 11 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 20 Mar 2018 New trial record